...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
【24h】

Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.

机译：过敏原特异性免疫疗法的发展：从过敏原提取物到过敏疫苗，绕过了过敏原特异性免疫球蛋白E和T细胞反应性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Allergen-specific immunotherapy (SIT) is the only specific and disease-modifying approach for the treatment of allergy but several disadvantages have limited its broad applicability. We argue that the majority of the possible disadvantages of SIT such as unwanted effects, poor efficacy and specificity as well as inconvenient application are related to the poor quality of natural allergen extracts, which are the active ingredients of all currently available allergy vaccines. Because of the progress made in the field of molecular allergen characterization, new allergy vaccines based on recombinant allergens, recombinant hypoallergenic allergen derivatives and allergen-derived T cell peptides have entered clinical testing and hold promise to reduce the side-effects and to increase the specificity as well as the efficacy of SIT. Here, we present a refined immunotherapy concept, which is based on the use of peptides derived from allergen surfaces that exhibit reduced, allergen-specific IgE as well as T cell reactivity. These peptides when fused to non-allergenic carriers give rise to allergen-specific protective IgG responses with T cell help from a non-allergenic carrier molecule. We summarize the experimental data demonstrating that such peptide vaccines can bypass allergen-specific IgE as well as T cell activation and may be administered at high doses without IgE- and T cell-mediated side-effects. Should these peptide vaccines prove efficacious and safe in clinical trials, it may become possible to develop convenient, safe and broadly applicable forms of SIT as true alternatives to symptomatic, drug-based allergy treatment.
机译：变应原特异性免疫疗法（SIT）是治疗变态反应的唯一特异性方法和疾病缓解方法，但是一些缺点限制了其广泛的适用性。我们认为，SIT的大多数可能弊端，例如不良影响，不良功效和特异性以及不方便使用，都与天然过敏原提取物质量差有关，后者是目前所有可用的过敏疫苗的活性成分。由于分子变应原表征领域的进展，基于重组变应原，重组低变应原变应原衍生物和变应原来源的T细胞肽的新型变应性疫苗已进入临床测试，有望减少副作用并提高特异性。以及SIT的功效。在这里，我们提出一种完善的免疫疗法概念，该概念基于使用源自变应原表面的肽，这些肽表现出降低的变应原特异性IgE以及T细胞反应性。这些肽与非变应原性载体融合后，可在非变应原性载体分子的T细胞帮助下引起变应原特异性保护性IgG反应。我们总结了表明这些肽疫苗可以绕过变应原特异性IgE以及T细胞活化的实验数据，可以高剂量给药而无IgE和T细胞介导的副作用。如果这些肽疫苗在临床试验中证明有效且安全，则有可能开发出方便，安全和广泛适用的SIT形式，作为对症，基于药物的变态反应治疗的真正替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号